Electroacupuncture frequency for chemotherapy-induced neuropathy in breast cancer: a randomized controlled trial.

ABSTRACT:

Background

Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent dose-limiting toxicity in breast cancer patients. Electroacupuncture (EA) shows promise but optimal stimulation parameters remain undefined. We conducted a randomized trial comparing EA frequencies for CIPN.

Methods

This single-center, single-blind trial randomized patients to 2, 100, and 2/100 Hz EA, or mecobalamin (Mecbl). The primary outcome was the patient neurotoxicity questionnaire (PNQ) response rate at Week 4. Secondary outcomes included PNQ scores, National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grades at Weeks 4/8, and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20 (E

SUBMITTER: Shen Q 

PROVIDER: S-EPMC12449621 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature